* a4 P/ ]; l; C3 N" r' N: H$ R& l
临床上有依维莫司联合EGFR TKI作为易/特耐药之后的方案的研究:2 D2 z) ^" K f0 J1 s6 f
Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.6 X+ _# Y7 F' M9 Z& S F http://www.ncbi.nlm.nih.gov/pubmed/22968184 ; e) \ K |# E" M ; h7 {* a( y" r! t依维莫司联合吉非替尼抑制非小细胞肺癌细胞系的效果和作用机制3 l: \+ F3 U9 c+ j5 l http://d.wanfangdata.com.cn/Thesis_Y1770447.aspx